Document is current
Any future updates will be listed below
-
Authors
Anzilotti, Serenella
Scarcella, Melania
Ciampa, Mariangela
Di Muraglia, Noemi
Anastasio, Camilla
Fiorentino, Chiara
Rossin, Federica
Avallone, Luigi
Pignataro, Giuseppe
Pavone, Luigi Michele
De Pasquale, Valeria https://orcid.org/0000-0001-5285-1980
- License Information
-
More Information
Article History
Received: 12 May 2025
Revised: 20 June 2025
Accepted: 15 July 2025
First Online: 1 August 2025
Competing interests
: LMP has licensed compositions comprising hepatocyte growth factor or variants thereof for use in the treatment of mucopolysaccharidoses (granted Italian patent MI2014A001454, Title “Compositions for the therapy of mucopolysaccharidoses”). The authors declare no additional competing financial interests.
: Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the Animal Facility of the Department of Molecular Medicine and Medical Biotechnology at the University of Naples Federico II (Naples, Italy) and authorized by the Italian Ministry of Health (Authorization n° 854/2021-PR). All procedures complied with the principles and procedures outlined in the ARRIVE guidelines and EU Directive 2010/63/EU for animal experiments. No human subjects, tissues, or clinical data were involved in this study; therefore, informed consent and consent for publication of human images are not applicable.
